LILRB2 and non-small cell lung carcinoma: To explore the impact of ILT4 blockade on the efficacy of PD-L1 inhibitor in TKI-resistant NSCLC, we first established gefitinib-resistant PC9 (PC9-GR) cells by long-term stimulation of parental PC9 cells with low-dose gefitinib.